Could a little-known drug really revolutionize treatment for autoimmune diseases, cancer, depression, and more?

"[LDN] raises hopes of reversing memory loss in old age."-the Guardian

Over 30,000 copies sold!

Low Dose Naltrexone (LDN) holds the potential to help millions of people suffering from various autoimmune diseases and cancers, and even autism, chronic fatigue, and depression, find relief. Administered off-label in small daily doses (0.5 to 4.5 mg), this generic drug is extremely affordable and presents few known side effects.

So why has it languished in relative medical obscurity?

The LDN Book explains:

• The drug's origins
• Its primary mechanism
• The latest research from practicing physicians and pharmacists

Compiled by Linda Elsegood of The LDN Research Trust-the world's largest LDN charity organization with over 19,000 members worldwide-the book features ten chapters contributed by medical professionals on LDN's efficacy and two patient-friendly appendices.

The LDN Book is a comprehensive resource for doctors, pharmacists, and patients who want to learn more about how LDN is helping people now, and a clarion call for further research that could help millions more.

About the Author
Linda Elsegood is the founder of the LDN Research Trust, which was set up in the UK as a Registered Charity in 2004, and is the editor of The LDN Book. Diagnosed with MS in August of 2000, she started LDN therapy in December of 2003, and now has a better quality of life and hope for the future. Through the Trust, she has connected thousands of patients, doctors, and pharmacists around the world with information, articles, and patient stories about LDN.

Reviews

"I first came across LDN several years ago when a medical colleague said I should look into its positive effects in patients with MS, Crohn's disease, and other autoimmune disorders. I was so impressed with what I read that I helped submit a petition to the UK government to ask for funding for further research into this inexpensive drug. But, as with so many petitions, no progress was made. I hope The LDN Book-which presents up-to-date findings that again confirm the efficacy of this safe, cheap, generic drug in helping to control many chronic, disabling conditions-is read by those in the Department of Health and by all doctors caring for patients with autoimmune disease. In the UK, LDN has been stranded in limbo; maybe now the time has come for it to be accepted as a recognized therapy that could, at least, be tried on those suffering such long-term diseases of the immune system."--Dr. Chris Steele, MBE, general practitioner; medical presenter on ITV's This Morning

"As a practicing physician who has used LDN as a cornerstone therapy for over fifteen years, I can say without equivocation that LDN is the most important and successful medicine I have ever used. I often joke that if not for LDN I couldn't pay my mortgage; I've had so many new patients referred to me by someone whose life has improved dramatically through the use of LDN. And despite my knowledge and experience with LDN, I've learned a great deal from The LDN Book-aspects of its basic science I hadn't known, new uses, and how its uses can inform us about the causes of various diseases. This is a wonderful book for any patient with an autoimmune disease, cancer, depression, or a host of other conditions and is a must-read for any physician whose goal is to help their patients."--Dr. Thomas Cowan, author of The Fourfold Path to Healing and coauthor of The Nourishing Traditions Book of Baby & Child Care

"Low Dose Naltrexone (LDN) was discovered by my husband and partner, Dr. Bernard Bihari. Incredibly informative and superbly written by various members of the medical profession sharing their experiences using this extraordinary drug, The LDN Book honors his legacy in helping patients suffering from autoimmune and other diseases to regain their health and their lives."--Jacqueline Young

Book Information
ISBN 9781603586641
Author Linda Elsegood
Format Paperback
Page Count 240
Imprint Chelsea Green Publishing Co
Publisher Chelsea Green Publishing Co
Weight(grams) 363g
Dimensions(mm) 229mm * 153mm * 13mm